One of the 100 limited-edition framed certificates we're sending to the first group of companies that signed up for an Enterprise plan

Un­lock the full End­points ex­pe­ri­ence for your com­pa­ny — and sup­port our mis­sion of in­de­pen­dent bio­phar­ma re­port­ing

I want to give read­ers a quick up­date on the most im­por­tant part of our busi­ness mod­el — pre­mi­um sub­scrip­tions. We have some cru­cial fi­nan­cial goals we hope to achieve by the end of the year, and the team here in Lawrence is ready to ship some swag to kick off this lim­it­ed De­cem­ber pro­mo­tion.

We of­fer two pre­mi­um plans — En­ter­prise for com­pa­nies ($1,000/year, un­lim­it­ed peo­ple), and In­sid­er for in­di­vid­u­als ($200/year). This month of De­cem­ber will be the last chance to en­roll at the orig­i­nal rates — which have re­mained flat since we launched them in 2017.

Both plans un­lock ac­cess to our en­tire pre­mi­um con­tent li­brary like 100 top VCs in bio­phar­ma, Re­al World End­points: the brave new world com­ing in build­ing fran­chise ther­a­pies, and the top 20 pre­clin­i­cal biotech deals, and much more. You get ac­cess to tools like down­load­ing ar­ti­cles to PDF, our VIP sup­port team, and most of all, you’re di­rect­ly fund­ing the fu­ture de­vel­op­ment of End­points. These plans have been the rea­son we’ve been able to make new ed­i­to­r­i­al hires, with more to come. And we’re adding new ben­e­fits next year: paid sub­scribers will have ex­clu­sive ac­cess to watch our an­nu­al event at JP Mor­gan live at no ad­di­tion­al cost.

  • In­di­vid­u­als — sign-up for In­sid­er. All of the ben­e­fits above plus the op­tion to dis­able all ad­ver­tis­ing across web and email, and dis­count­ed tick­ets to End­points events. $200/year, end­ing soon.
  • Com­pa­nies — sign-up for En­ter­prise. Cov­ers every­one at your or­ga­ni­za­tion for $1,000/year. In­cludes a reprint li­cense to re­pur­pose and dis­trib­ute End­points con­tent in­ter­nal­ly. All em­ploy­ees will al­so be­gin to see a new “Your com­pa­ny sup­ports in­de­pen­dent jour­nal­ism” ban­ner in their dai­ly email re­ports.

By up­grad­ing, you’re di­rect­ly sup­port­ing in­de­pen­dent bio­phar­ma re­port­ing, and we’re look­ing for ways big and small to help pro­mote that among our read­ers. And that’s where the swag comes in.

The next 100 In­sid­er ac­counts to sign-up will re­ceive these vinyl stick­ers — 4 in a se­ries — that our stu­dio cre­at­ed.

And the next new 25 En­ter­prise sub­scribers will get stick­ers plus one of these amaz­ing­ly com­fort­able hood­ies. (Our sup­port team will reach out to get your pre­ferred size!)

Fi­nal­ly, the stu­dio cre­at­ed 100 lim­it­ed edi­tion framed cer­tifi­cates in hon­or of the very first batch of com­pa­nies who signed up for the En­ter­prise plan back when we launched it in the sum­mer of 2017. You can see a copy of what they look like at the top of this post.

These sub­scrip­tion plans helped End­points scale up to where we are to­day: serv­ing 400,000 unique read­ers per month on the web and near­ly 70,000 bio­phar­ma pros dai­ly by email, sup­port­ed by a glob­al­ly dis­trib­uted work­force, 15-strong and grow­ing, head­quar­tered in Lawrence, Kansas.

And we have big plans for 2020 — new cov­er­age ar­eas, prod­ucts, and deep­er re­port­ing on the peo­ple and trends that shape the bio­phar­ma world. The best way to help us get there is up­grad­ing to In­sid­er or En­ter­prise.

If you de­pend on End­points, it’s a sure bet we de­pend on you too. So please join us now be­fore De­cem­ber 31 while our orig­i­nal In­sid­er and En­ter­prise rates re­main. You can al­ways con­tact our help­ful sup­port team at help@end­pointsnews.com or by vis­it­ing your Read­er Pro­file.

FDA hands Mor­phoSys and In­cyte a quick OK on their po­ten­tial block­buster CAR-T al­ter­na­tive

Nearly three years after okaying the CAR-Ts Yescarta and Kymriah, the FDA has approved a new CD19 therapy.

MorphoSys’ Monjuvi, or tafasitamab-cxix, was cleared Friday for use in refractory diffuse large B-cell lymphoma (DBLCL). The approval sets up both MorphoSys and their commercial partner Incyte to compete with Gilead and Novartis in the ultra-competitive indication, where similar trial results and far easier delivery could allow them to cut a fair share of the market.

Rich Heyman (ARCH)

Rich Hey­man joins PMV Phar­ma, a p53 biotech, as it adds $70 mil­lion in Se­ries D

Less than a year after pulling in an impressive $62 million Series C round, PMV Pharma is back at it again.

The Cranbury, NJ-based biotech announced Monday an additional $70 million in Series D financing as it seeks to develop cancer therapies targeting p53 mutations. Additionally, PMV also introduced longtime biotech entrepreneur Rich Heyman as chairman of the board of directors.

“This financing provides PMV Pharma with the resources to expand our pipeline and to potentially advance multiple p53 therapies into the clinic,” said PMV president and CEO David Mack in a statement.

Days af­ter seal­ing Sanofi pact, Kymera beats a path to the Nas­daq with $100M IPO pitch

Back in March, when Kymera Therapeutics closed $102 million in Series C funding led by Biotechnology Value Fund and Redmile Group, CEO Nello Mainolfi noted the protein degradation player was “at the cusp of transitioning” into a fully integrated R&D company. Five months and a major Sanofi pact later, he’s back asking for another little push to get there.

Kymera has penciled in $100 million in its first IPO pitch — although given the public market’s seemingly insatiable appetite for biotechs these days the final figure is anyone’s guess.

CymaBay flash­es pos­i­tive re­sults from the tri­al they have to re­launch

Two weeks after the FDA lifted its clinical hold on their lead drug, CymaBay said it showed positive results in an aborted Phase III trial.

The drug, a small molecule known as seladelpar, had been in development for three different liver conditions before an independent review of a NASH study last year showed that it might actually be damaging patient’s liver cells. The FDA slapped a clinical hold across all three trials, only lifting it last month when an FDA review determined that the drug hadn’t caused liver damage.

Covid-19 roundup: Eli Lil­ly retro­fits RVs for first-of-its-kind an­ti­body tri­al with NIH; Am­gen, Ab­b­Vie, Take­da team on a drug

Eli Lilly and the NIH are about to start a first-of-its-kind trial that researchers and developers have talked about for months as a way of providing temporary immunity to the most at-risk populations.

Lilly announced this morning that it will start a 2,400-person trial with the National Institute for Allergy and Infectious Diseases to test whether its experimental Covid-19 neutralizing antibody can prevent people in nursing homes and assisted living facilities from developing the disease. The idea, known as passive immunity, is that rather than waiting on a vaccine to induce people to develop antibodies, doctors can give them lab-grown antibodies. Ideally, those antibodies will either attack the new SARS-CoV-2 infection, if the patient has recently been exposed, or persist in the blood for several weeks and prevent infection or disease for that period.

So Covid-19 leader BioN­Tech has a can­cer vac­cine in de­vel­op­ment? Yes, and Re­gen­eron just jumped in for the PhII com­bo study

Before the coronavirus global emergency stole the R&D show in biopharma, the leaders in the race to develop new mRNA therapies had a big interest in determining if their tech could be used to create an effective cancer vaccine after all the first-gen tries had failed to impress. So perhaps it’s not surprising that an early cut of the data at frontrunner BioNTech went largely unnoticed.

Unless you were at Regeneron.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Sev­en plucky di­ag­nos­tics com­pa­nies win a $249M round of con­tracts af­ter sur­viv­ing NI­H's Covid-19 'Shark Tank' com­pe­ti­tion

As US Covid-19 deaths creep past 150,000 and officials stress the importance of contact tracing, the NIH’s Rapid Acceleration of Diagnostics (RADx) program has inked contracts totaling $248.7 million to expand testing capabilities.

The seven contracts, which were chosen “Shark Tank”-style from a pool of 100 proposals, are part of an effort to bump daily testing capacity to 2% of the country’s population by late summer or fall. That would be about 6 million people per day, compared to the current 520,000 to 823,000 tests being administered daily.

Im­mu­nic's lead MS drug hits pri­ma­ry and key sec­ondary end­points in PhII, but ques­tions re­main

Just a week after its lead program began enrolling patients in a study to treat Covid-19, Immunic Therapeutics is making more waves.

This time, the biotech is providing a glimpse at topline data from a Phase II trial studying the efficacy of vidofludimus calcium, or IMU-838, in relapsing-remitting multiple sclerosis patients. Taken orally, the candidate met its primary endpoint in reducing the cumulative number of combined unique active MRI lesions after 24 weeks for a 45 mg dose compared to a placebo, as well as a key secondary endpoint in such reductions for the 30 mg dose.

Frank Zhang (AP Images)

CAR-T fil­ing in sight, Frank Zhang grabs full con­trol of J&J-part­nered Leg­end Biotech, steps down from Gen­Script

Two months after Yuan Xu steered Legend Biotech to a $424 million public debut on the Nasdaq, founder and chairman Frank Zhang is grabbing the reins as CEO.

In conjunction with the move, Zhang is also stepping down from the helm of GenScript — a position he’s held for 18 years. GenScript, a Hong Kong-listed CRO, hatched Legend as a subsidiary in 2015 before spinning it out, and remains a majority shareholder.